Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BPDCN”

25 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 25 results

Testing effectiveness (Phase 2)UnknownNCT03599960
What this trial is testing

Combination Chemotherapy in Patients With Newly Diagnosed BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Centre Hospitalier Universitaire de Besancon 26
Not applicableLooking for participantsNCT05430971
What this trial is testing

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Immune Oncology Research Institute 200
Testing effectiveness (Phase 2)Ended earlyNCT04342962
What this trial is testing

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 25
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Early research (Phase 1)Ended earlyNCT03203369
What this trial is testing

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cellectis S.A. 1
Testing effectiveness (Phase 2)Ended earlyNCT05086315
What this trial is testing

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia RefractoryMyelodysplastic Syndromes+1 more
Sanofi 101
Testing effectiveness (Phase 2)Active Not RecruitingNCT03386513
What this trial is testing

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
AbbVie 179
Testing effectiveness (Phase 2)Ended earlyNCT04317781
What this trial is testing

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Study completedNCT02420873
What this trial is testing

An Open-label Phase II Study of Lorvotuzumab Mertansine

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 9
Early research (Phase 1)Active Not RecruitingNCT04013685
What this trial is testing

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic Syndromes+3 more
Orca Biosystems, Inc. 155
Early research (Phase 1)Looking for participantsNCT04318678
What this trial is testing

CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)

Who this might be right for
AML/MDSB-ALLT-ALL+1 more
St. Jude Children's Research Hospital 108
Very early researchLooking for participantsNCT06765876
What this trial is testing

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Who this might be right for
Leukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic 18
Testing effectiveness (Phase 2)Looking for participantsNCT04216524
What this trial is testing

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center 40
Early research (Phase 1)Looking for participantsNCT06690827
What this trial is testing

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Who this might be right for
AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd 30
Early research (Phase 1)Looking for participantsNCT03113643
What this trial is testing

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Myeloid LeukemiaMyelodysplastic SyndromeBlastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 72
Testing effectiveness (Phase 2)Looking for participantsNCT06006403
What this trial is testing

Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Relapse Leukemia+1 more
Chongqing Precision Biotech Co., Ltd 36
Early research (Phase 1)Study completedNCT03485547
What this trial is testing

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 5
Early research (Phase 1)Study completedNCT02730312
What this trial is testing

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Who this might be right for
Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm+1 more
Xencor, Inc. 120
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07007052
What this trial is testing

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
French Innovative Leukemia Organisation 33
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Load More Results